Formulations of 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione, and methods of making and using same
This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.
1. A process for producing a liquid comprising a quantity of crystals of 4-methyl-5-(pyrazine-2-yl)-3H-1,2-dithiole-3-thione (“oltipraz”), the process comprising the steps of:
i) combining poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, water, polysorbate and oltipraz to create a suspension vehicle; and
ii) wet milling the suspension vehicle to produce the liquid composition comprising crystals of oltipraz,
wherein, based on the weight of the suspension vehicle prior to the addition of any bulking agent, from 1 to 25 wt % poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, water, from 1 to 5 wt % polysorbate and from about 4 to about 15 wt % oltipraz is stirred to create the suspension vehicle, and wherein the suspension vehicle is wet-milled until the mean hydrodynamic diameter (MDH) with a Z-average of the oltipraz crystals in the suspension is from 100 nm and 800 nm, as measured by dynamic light scattering at 25° C. on a suspension of the crystals in water at a concentration of 0.01 to 0.1 mg of crystals per mL of water.
2. A process according to claim 1 , wherein the process further comprises the step:
iii) adding a bulking agent, wherein the bulking agent is selected from the group consisting of polyvinylpyrrolidones and cellulosic polymers, to the liquid composition comprising crystals of oltipraz produced in step (i).
3. A process according to claim 2 , the process further comprising the step:
iv) removing the liquid from the liquid composition comprising crystals of oltipraz to form a dry composition, wherein removing the liquid composition comprises the step of spray-drying or lyophilizing the liquid composition.
4. A process for producing a composition comprising a quantity of crystals of 4-methyl-5-(pyrazine-2-yl)-3H-1,2-dithiole-3-thione (“oltipraz”), the process comprising the step of:
wet milling a suspension vehicle comprising poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, water, polysorbate and oltipraz to produce a liquid composition comprising crystals of oltipraz;
wherein about 4.3 wt % poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) 1:2:0.2, about 85 wt % purified water, about 2.1 wt % polysorbate and about 8.6 wt % oltipraz is stirred to create the suspension vehicle, and wherein the suspension vehicle is wet-milled until the mean hydrodynamic diameter (MDH) with a Z-average of the oltipraz crystals in the suspension is from 100 nm and 800 nm, as measured by dynamic light scattering at 25° C. on a suspension of the crystals in water at a concentration of 0.01 to 0.1 mg of crystals per mL of water.
5. A process according to claim 4 , wherein polyvinylpyrrolidone is added to the suspension vehicle and then additional purified water is added to dilute the suspension to below about 28 wt % total solids.
6. A process according to claim 1 , wherein wet milling yields a quantity of oltipraz crystals that have a MHD from about 300 to 800 nm.
7. A process according to claim 1 , wherein the quantity of oltipraz crystals will have a MHD of from 100 nm to 800 nm if left in water at 25° C. for at least 1 hour.
8. A process according to claim 1 , wherein the quantity of crystals comprises substantially the entire quantity of oltipraz present in the liquid composition.
9. A process according to claim 1 , wherein the quantity of crystals of oltipraz comprises less than 20% by weight of the liquid composition.
10. A process according to claim 2 , wherein the liquid composition comprises the bulking agent at less than 30 percent by weight of the liquid composition comprising the bulking agent and crystals of oltipraz.
11. A process according to claim 1 , wherein the polydispersity index (PdI) of the crystals in the quantity of oltipraz crystals after the wet milling is less than 0.80, wherein PdI=(σ/d) 2 , wherein σ is the standard deviation and d is the Z-average hydrodynamic diameter.
12. A process according to claim 1 , wherein the polysorbate in the liquid composition comprising the crystals of oltipraz comprises polysorbate 80 in an amount from 1 to 5 percent by weight of the liquid composition.
13. A process according to claim 1 , further comprising the step of combining a bulking agent with at least a portion of said liquid composition comprising crystals of oltipraz to form a liquid composition comprising the bulking agent and crystals of oltipraz.
14. A process according to claim 13 , wherein the bulking agent comprises a copolymer of polyvinylpyrrolidone and poly(vinyl acetate) with a ratio of approximately 6:4 of vinylpyrrolidone and vinyl acetate monomers.
15. A process according to claim 13 , wherein the liquid composition comprising the bulking agent and crystals of oltipraz comprises from 5% to 35% by weight, or more than 35% by weight total solids of the liquid composition.
16. A process according to claim 13 , further comprising one or more steps to form a dry composition that substantially excludes liquid, wherein the one or more steps comprise the step of spray drying the liquid composition comprising the bulking agent and crystals of oltipraz.
17. A process according to claim 13 , further comprising one or more steps to form a dry composition that substantially excludes liquid, wherein the one or more steps comprise the step of lyophilizing the liquid composition comprising the bulking agent and crystals of oltipraz.
18. A process according to claim 13 , wherein the liquid composition comprises less than 1 percent of drug-degradant impurities relative to the oltipraz in the liquid composition and less than 2 percent total impurities relative to the oltipraz in the liquid composition.
19. A process according to claim 13 , wherein the liquid composition comprising the bulking agent and crystals of oltipraz comprises less than 0.5 percent of drug-degradant impurities relative to the oltipraz in the liquid composition and less than 1 percent total impurities relative to the oltipraz in the liquid composition.